Advagene Biopharma's nasal spray immune-modulating protein technology platform is attracting attention from the international medical community! General Manager Hsu You-shen announced during a press conference on the 24th that their AD17002, due to its unique treatment mechanism, has already signed confidentiality agreements with several foreign companies to evaluate collaborative projects and discuss business licensing opportunities both domestically and internationally.
Hsu stated that due to its unique treatment mechanism, AD17002 has the potential to be used in the treatment and prevention of various respiratory infections. In addition to treating COVID-19 pneumonia, it is also being used in the treatment of respiratory allergies and severe asthma. Clinical trials for various medications are progressing smoothly, and efforts to strengthen the global patent layout are underway.
He mentioned that AD17002's superior clinical data for treating COVID-19 pneumonia has led to an invitation to a meeting with the Biomedical Advanced Research and Development Authority (BARDA) in the United States, attracting interest and attention from expert attendees. Based on expert recommendations, further collaborative projects will be applied for.
Moreover, Advagene Biopharma will soon sign a confidentiality agreement with a global non-profit health organization to evaluate and discuss follow-up cooperation for pandemic respiratory infectious diseases.
Hsu further explained that in the development of medications for severe asthma, approximately 17% of asthma patients have severe asthma. This subgroup has excessive eosinophils in the blood, leading to severe airway inflammation that existing steroid medications cannot effectively control. They often require expensive antibody medications administered at high doses, which significantly affect their quality of life. AD17002 aims to address this unmet medical need with its unique mechanism of action, nasal spray convenience, and price advantage. It is expected to fill this medical gap. The global market for severe asthma medications targeting eosinophils is approximately $25 billion, estimated to reach $15 billion by 2032.
AD17002 works by inducing the production of type I interferons by respiratory epithelial cells to regulate immune-inflammatory factors, including eosinophils, thereby improving asthma. Unlike existing medications that provide symptomatic relief or immunosuppression, and being a nasal spray, patients can self-administer without the need for inhalation effort, making it convenient to use. Moreover, nasal spray is a local medication with low dosage, resulting in fewer side effects compared to systemic medications such as injections or oral administration. AD17002 is currently undergoing Phase II clinical trials for severe asthma at National Taiwan University Hospital, with smooth recruitment.
Hsu stated that asthma and allergic rhinitis are both inflammatory respiratory diseases, and they often coexist. AD17002 has previously completed Phase I/II clinical trials for treating dust mite allergic rhinitis, with results showing good safety and tolerability, as well as preliminary effectiveness data. Therefore, there is a positive outlook for the Phase II clinical efficacy of AD17002 in treating severe asthma, with preliminary data expected to be available in the third quarter of this year.
Advagene Biopharma is one of the few companies globally with innovative technology for "nasal spray protein." Through its independently developed LTh(αK) immune-modulating protein technology platform, it has not only pioneered the development of domestic nasal spray vaccines but also globally pioneered the development of new drugs for multiple indications, including allergic rhinitis, severe asthma, and COVID-19 pneumonia. These drugs have entered different stages of clinical trials, demonstrating the enormous medical and commercial value of the LTh(αK) platform.
Looking ahead, Hsu stated that in addition to continuing to advance clinical trials for their new drugs, they will intensify their efforts in business strategy layout this year. They have recently signed confidentiality agreements with several foreign companies to evaluate potential future collaborative licensing opportunities. They have also initiated early-stage collaborative development with several domestic companies, aiming to actively explore the diverse applications of the LTh(αK) platform combined with nasal spray, providing patients with new treatment options.
Resource (Mandarin):
